E-ISSN: 1308-5255 ISSN: 1307-7635
Risk of Cutaneous Malignancy in Mycosis Fungoides Patients Treated with PUVA: A Retrospective Study
PDF
Cite
Share
Request
Original Investigation
VOLUME: 9 ISSUE: 1
P: 12-17
March 2015

Risk of Cutaneous Malignancy in Mycosis Fungoides Patients Treated with PUVA: A Retrospective Study

Turk J Dermatol 2015;9(1):12-17
DOI: 10.4274/tdd.2413
Melike Umarova Aslan
Algün Polat Ekinci
Can Baykal
1. Istanbul Üniversitesi Istanbul Tip Fakültesi, Dermatoloji Anabilim Dali, Istanbul, Türkiye
No information available.
No information available
Received Date: 27.08.2014
Accepted Date: 02.12.2014
PDF
Cite
Share
Request

ABSTRACT

Objective:

PUVA therapy is mostly used longer than other diseases in mycosis fungoides (MF) patients. We aimed to investigate the chronic side effects of PUVA therapy, including skin cancer to disclose the actual risk in Turkish population.

Methods:

We screened all MF patients treated with PUVA at the Department of Dermatology and Venereology of İstanbul Medical Faculty and included patients in whom PUVA has first initiated between 1994 and 2006 and administered in one or several courses and who were followed up more than five years with last visit in 2012.

Results:

Fifty patients with MF had a mean follow-up duration of 10.2±2.8 years. Six patients (12%) had PUVA lentigines. Two of them (4%) developed skin cancer (basal cell carcinoma, Bowen’s disease) during their follow-up. The mean sessions (295.5±7.8 sessions) and total UVA doses (1452 J/cm2) in these patients with skin cancer were higher than those who did not develop skin cancer (128.7±73 sessions and 515±31 J/cm2, respectively). There was a significant relationship between the PUVA lentigines and development of cutaneous malignancy (p=0.01).

Conclusion:

Cutaneous malignancies were detected in 4% of MF patients followed up approximately 10 years. Due to this low risk, we conclude that PUVA therapy is relatively safe in patients with MF in our country. However, UVA should not be applied in high total doses and patients should be followed-up lifelong.